Look Closely, Make Money: Aixtron, ASML, Bayer, Infineon, Nvidia and Zefiro Methane

Chip Shock Hits ASML, Nvidia, Infineon, and Aixtron: Is the AI Rally Over?

It was not a major Wall Street crash—and that is precisely what makes the start of the week so striking. While the Nasdaq lost just 0.56% and Meta and Alphabet actually gained ground, the Philadelphia Semiconductor Index plummeted 5.9% to around 11,131 points. Nvidia shares fell 3.4% to USD 210.96. Thus, the selling pressure struck the very heart of the AI bull market. The trigger was warnings from leading AI executives about a development pace that is too rapid and virtually uncontrollable. Added to this were rising US yields, which weigh particularly heavily on highly valued growth stocks. Investors are thus questioning not so much the future of artificial intelligence as the enormous valuations and the speed at which billions are flowing into data centres and new chips. The significant gap between the Nasdaq’s moderate decline and the SOX’s plunge shows that, so far, this has primarily been a revaluation of the semiconductor industry.

This nervousness spread throughout the entire supply chain. AMD lost about 4%, while Broadcom, Micron, and Taiwan Semiconductor also fell. In Europe, ASML was hit particularly hard. The stock of Europe’s most valuable publicly traded company plummeted by nearly 7%. As a virtually irreplaceable supplier of state-of-the-art lithography equipment, ASML is considered a key supplier to the chip boom. The decline therefore sends a stronger signal than the loss of an ordinary technology stock.

Even broadly diversified sector funds were unable to escape the downturn. The VanEck Semiconductor UCITS ETF and the iShares MSCI Global Semiconductors UCITS ETF came under pressure. While diversifying across many stocks within the semiconductor sector reduces the risk associated with individual companies, investors remain fully exposed to an industry-wide shift in sentiment. The high weighting of a few market leaders makes the sector even more vulnerable to rapid shifts in sentiment.

In Germany, Aixtron was hit particularly hard, falling by about 11.2%. SÜSS MicroTec lost 9.5%, Siltronic 8.9%, and Infineon about 7.7%. Jenoptik and Elmos Semiconductor also fell significantly. Notably, former market darlings outside the traditional chip sector were also sold off: Friedrich Vorwerk fell about 10 to 11%, depending on the exchange, while Siemens Energy fell about 8%. This points to additional profit-taking in German stocks that had performed strongly.

From a technical analysis perspective, the situation remains tense. The SOX is trading below the 20-day, 50-day, and 100-day moving averages but is still holding above the rising 200-day moving average at around 9,973 points.

At the same time, Nvidia is struggling at the 50-day and 100-day moving averages at approximately USD 213 and USD 211, respectively. If this support zone breaks down, the 200-day MA near USD 198 could come into focus. The AI rally is not over yet. However, if Nvidia and the SOX fail to stage a quick rebound, a bad trading day could turn into a deeper correction across the entire chip sector.

Zefiro Methane: More Orders, More Visibility

Zefiro Methane is positioning itself in the US in a market that is growing significantly each year due to stricter environmental regulations, public subsidies, and the expansion of new energy infrastructure. The company focuses on the remediation of abandoned and orphaned oil and gas wells; properly plugging these wells not only reduces emissions but also frees up land for new industrial, grid, and energy projects. As a result, the company’s operational performance is less directly tied to commodity prices and more closely linked to regulatory pressure, government incentive programs, and investment decisions in the infrastructure sector. Especially against the backdrop of growing investments in power grids, flexible natural gas power plant capacity, and the development of many new data centre locations, a service provider like Zefiro in a niche market should benefit disproportionately.

This is already becoming apparent again on the order side this year. According to the company, Zefiro is now active in 13 US states, thereby tapping into a broader base of public tenders and private-sector projects. Previously announced agreements, including a 3-year contract worth approximately USD 19.6 million in Ohio and a methane monitoring contract worth around USD 850,000 in West Virginia, point to increasing operational visibility. In addition, a state-funded well-plugging contract, worth up to USD 11.5 million and running through June 2029, improves revenue visibility and planning.

Three additional state-funded well-plugging projects in Ohio and Pennsylvania have now been added, with a combined contract value of approximately USD 1.9 million. Notably, Zefiro was the sole bidder for two of these three contracts, suggesting local market knowledge, operational readiness, and a certain barrier to entry in the fragmented competitive landscape. For investors, this is more than just an isolated announcement. These government contract awards support the growth thesis that contract wins are accelerating and that Zefiro is already being recognized as a reliable execution partner in the publicly funded remediation market. Together with the expansion of its equipment and operating fleet, this also increases the likelihood that the company can run multiple campaigns in parallel, enabling it to take on new contracts faster and convert them into revenue more quickly.

It also remains strategically interesting that Zefiro aims to monetize proven emissions reductions beyond its traditional service business. This can increase value creation per project, even though CO₂ credits are significantly more volatile than the actual well remediation work itself. The recent intensification of investor relations activity fits the profile of a company that, amid a growing stream of corporate news, also aims to raise its profile in capital markets. All in all, this paints a picture of a provider benefiting from a structurally growing remediation market. The key question in the coming months will be whether the company can sustainably translate the rising number of projects into high-margin growth and robust cash flows.

Bayer on the Verge of a Billion-Euro Turning Point: Can This Deal Finally Solve the Glyphosate Problem?

The Bayer Group may be facing one of its most important turning points since the Monsanto acquisition. While the share price has recently hovered steadily around EUR 49, a settlement is being decided in the US that could make a significant portion of the long-standing glyphosate risks more predictable. The total amount at stake is up to USD 7.25 billion—significantly more than a typical court ruling. The Leverkusen-based company aims to settle approximately 65,000 existing Roundup claims, as well as numerous potential future claims, through its Monsanto subsidiary. Payments ranging from USD 10,000 to USD 165,000 per eligible claimant are planned. The exact amount depends, among other factors, on age, medical condition, and the nature of Roundup use. The settlement is to be financed through annual payments over a period of up to 21 years.

At the hearing on September 14, however, Bayer did not receive a final ruling. Judge Timothy Boyer requested further written submissions from both supporters and opponents. No date was set for the ruling. This uncertainty explains why Bayer’s stock has shown little reaction so far: investors are waiting to see whether the multi-billion plan will result in a binding settlement.

Bayer’s position today is more favourable than it was at the beginning of the year. In June, the US Supreme Court ruled in favour of Monsanto in the Durnell case. The ruling weakened lawsuits based on alleged missing cancer warnings on product packaging. Several plaintiffs who initially wanted to withdraw from the settlement are said to have changed their position as a result. For Bayer, this increases the chance of settling a large portion of the pending cases under a single framework.

Nevertheless, approval is not certain. Opponents consider the proposed compensation too low and doubt that a Missouri court has the authority to bind potential future plaintiffs from other US states. Furthermore, the planned compensation for the attorneys involved has drawn criticism. Bayer, for its part, emphasizes that the settlement is fair and the only realistic way to resolve the complex legal issues that have weighed on the company for years.

From a technical analysis perspective, the Bayer stock appears surprisingly stable. Trading at around EUR 49.21, it is just above the 20-day and 50-day moving averages (MA20 and MA50) at approximately EUR 48.86 and EUR 48.56, respectively. The 100-day moving average (MA100) at around EUR 43.88 and the 200-day moving average (MA200) near EUR 41.97 also continue to point upward. The range between EUR 48 and EUR 49 thus forms the short-term support level. Above EUR 50, the share price could once again move toward the summer high of around EUR 54. However, the apparent calm should not be misleading. Approval would give Bayer greater planning certainty and could drive the stock above EUR 50. A rejection or extensive additional demands from the court, on the other hand, are likely to trigger new uncertainty. The USD 7.25 billion settlement does not automatically end all glyphosate lawsuits—but it could be the most important step yet toward finally bringing Bayer’s biggest legacy liability under control.

ASML, Nvidia, Infineon, and Aixtron are facing a sharp industry correction. Still, it remains to be seen whether this will result in merely a short-term revaluation or an actual cooling-off in the AI sector. Zefiro Methane is benefiting from government-funded remediation projects and a growing order book in a market gaining momentum from regulation and infrastructure investments. Bayer faces a potential billion-dollar turning point in the glyphosate complex, the outcome of which will likely determine whether the stock gains greater planning certainty or faces new uncertainty.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.